Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy)
Ernest R. Somerville,
Ernest R. Somerville
Institute of Neurological Sciences, Prince of Wales Hospital and University of New South Wales, Sydney, Australia
Search for more papers by this authorErnest R. Somerville,
Ernest R. Somerville
Institute of Neurological Sciences, Prince of Wales Hospital and University of New South Wales, Sydney, Australia
Search for more papers by this authorAddress correspondence to Ernest R Somerville, Institute of Neurological Sciences, Prince of Wales Hospital, Barker Street, Randwick NSW 2031, Australia. E-mail: [email protected]
Summary
Seizure aggravation by antiepileptic drugs (AEDs) is a rare phenomenon, occurring mostly in generalized epilepsies treated with drugs that are more efficacious against partial seizures. Its frequency is greatly overestimated by doctors and especially by patients. There are many other reasons for seizures to deteriorate but they are often not considered. Seizure aggravation by AEDs is important to recognize but equally important not to overdiagnose. It can largely be prevented by accurate syndromic diagnosis and the treatment of generalized epilepsies with drugs that are effective against primary generalized seizures and avoiding those that are not.
References
- Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. (1994) Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The international gabapentin study group. Epilepsia 35: 795–801.
- Bauer J. (1996) Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand 94: 367–377.
- Berkovic SF. (1998) Aggravation of generalized epilepsies. Epilepsia 39(suppl 3): S11–14.
- Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U. (2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69: 1751–1760.
- Chaves J, Sander JW. (2005) Seizure aggravation in idiopathic generalized epilepsies. Epilepsia 46(suppl 9): 133–139.
- Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. (1999) New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40: 590–600.
- Flowers CM, Racoosin JA, Kortepeter C. (2006) Seizure activity and off-label use of tiagabine. N Engl J Med 354: 773–774.
- Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A. (2004) Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 45: 1282–1286.
- Genton P. (2000) When antiepileptic drugs aggravate epilepsy. Brain Dev 22: 75–80.
- Genton P, Gelisse P, Thomas P, Dravet C. (2000) Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 55: 1106–1109.
- Guerrini R, Belmonte A, Genton P. (1998a) Antiepileptic drug-induced worsening of seizures in children. Epilepsia 39(suppl 3): S2–10.
- Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. (1998b) Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39: 508–512.
- Horn CS, Ater SB, Hurst DL. (1986) Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol 2: 340–345.
- Kazzi ZN, Jones CC, Morgan BW. (2006) Seizures in a pediatric patient with a tiagabine overdose. J Med Toxicol 2: 160–162.
- Koepp MJ, Edwards M, Collins J, Farrel F, Smith S. (2005) Status epilepticus and tiagabine therapy revisited. Epilepsia 46: 1625–1632.
- Liu L, Zheng T, Morris MJ, Wallengren C, Clarke AL, Reid CA, Petrou S, O’Brien TJ. (2006) The mechanism of carbamazepine aggravation of absence seizures. J Pharmacol Exp Ther 319: 790–798.
- Marescaux C, Vergnes M, Depaulis A. (1992) Genetic absence epilepsy in rats from Strasbourg – a review. J Neural Transm Suppl 35: 37–69.
- Marini C, Parmeggiani L, Masi G, D’arcangelo G, Guerrini R. (2005) Nonconvulsive status epilepticus precipitated by carbamazepine presenting as dissociative and affective disorders in adolescents. J Child Neurol 20: 693–696.
- Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, Lineberry CG. (1993) Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. lamotrigine protocol 05 clinical trial group. Neurology 43: 2284–2291.
- Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J. (2008) Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70: 607–616.
- Perucca E, Gram L, Avanzini G, Dulac O. (1998) Antiepileptic drugs as a cause of worsening seizures. Epilepsia 39: 5–17.
- Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. (2008) Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med 5: e166.
- Sazgar M, Bourgeois BF. (2005) Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol 33: 227–234.
- Schmidt D. (1998) Drug trials in epilepsy: a physicians’ guide. Taylor & Francis, London.
- Seymour JF. (1993) Carbamazepine overdose. Features of 33 cases. Drug Saf 8: 81–88.
- So EL, Ruggles KH, Cascino GD, Ahmann PA, Weatherford KW. (1994) Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide. Ann Neurol 35: 743–746.
- Somerville ER. (2002) Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 59: 79–83.
- Somerville ER. (2008) Lack of seizure aggravation by levetiracetam in idiopathic generalized epilepsy: evidence from clinical trials. Epilepsia 49(suppl 7): S456–457.
- Spiller HA, Winter ML, Ryan M, Krenzelok EP, Anderson DL, Thompson M, Kumar S. (2005) Retrospective evaluation of tiagabine overdose. Clin Toxicol (Phila) 43: 855–859.
- Tassinari CA, Dravet C, Roger J, Cano JP, Gastaut H. (1972) Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 13: 421–435.
- Trudeau V, Myers S, Lamoreaux L, Anhut H, Garofalo E, Ebersole J. (1996) Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 11: 470–475.
- UK Gabapentin Study Group. (1990) Gabapentin in partial epilepsy. Lancet 335: 1114–1117.
- US Food and Drug Administration. (2009a) Depakote approved labeling. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018723s039lbl.pdf. Accessed July 14, 2009.
- US Food and Drug Administration. (2009b) Zonegran approved labeling. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020789s022s025lbl.pdf. Accessed July 14, 2009.
- Vendrame M, Khurana DS, Cruz M, Melvin J, Valencia I, Legido A, Kothare SV. (2007) Aggravation of seizures and/or EEG features in children treated with oxcarbazepine monotherapy. Epilepsia 48: 2116–2120.
- Wallengren C, Li S, Morris MJ, Jupp B, O’Brien TJ. (2005) Aggravation of absence seizures by carbamazepine in a genetic rat model does not induce neuronal c-Fos activation. Clin Neuropharmacol 28: 60–65.
- Zheng T, Clarke AL, Morris MJ, Reid CA, Petrou S, O’Brien TJ. (2009) Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. Epilepsia 50: 83–87.
Citing Literature
